WRBY Warby Parker Inc.
Ophthalmic Goods · NYSE · SEC CIK 1504776 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.9%
TTM net income YoY942.0%
TTM EPS YoY216,172,782,113,783,936.0%
Revenue 3-yr CAGR12.6%
Net income 3-yr CAGR—
Margins
Gross margin54.7%
Operating margin0.2%
Net margin0.8%
FCF margin2.3%
EBITDA margin6.1%
Returns
ROE1.9%
ROA1.0%
ROIC (approx.)1.1%
Asset turnover1.25x
Leverage & solvency
Liabilities / assets49.1%
Debt / equity0.00x
Current ratio2.26x
Interest coverage—
Cash quality & payout
Operating cash flow / net income13.67x
Accruals ratio-12.6%
Payout ratio—
Capex / revenue8.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $244.74M | $235.51M | $242.45M | $211.97M | $221.68M | $214.47M | $223.78M | $190.64M |
| Cost of revenue | $111.56M | $99.05M | $111.41M | $100.92M | $101.73M | $100.87M | $97.80M | $87.52M |
| Gross profit | $133.17M | $136.46M | $131.04M | $111.04M | $119.94M | $113.61M | $125.98M | $103.13M |
| SG&A expense | $129.61M | $133.29M | $129.37M | $117.89M | $116.38M | $118.13M | $123.51M | $112.54M |
| Operating income | $3.56M | $3.17M | $1.67M | -$6.85M | $3.57M | -$4.53M | $2.47M | -$9.42M |
| Pretax income | $6.17M | $5.25M | $4.00M | -$5.09M | $5.75M | -$2.54M | $4.93M | -$6.78M |
| Income tax | $563,000 | $607,000 | $821,000 | $862,000 | -$125,000 | -$789,000 | $1.45M | $93,000 |
| Net income | $5.60M | $4.64M | $3.18M | -$5.95M | $5.87M | -$1.75M | $3.47M | -$6.88M |
| EBITDA | $17.99M | $17.24M | $15.44M | $6.25M | $16.10M | $7.96M | $14.63M | $2.92M |
| EPS (basic) | 0.04 | 0.04 | 0.03 | — | 0.05 | -0.01 | 0.03 | — |
| EPS (diluted) | 0.04 | 0.04 | 0.03 | — | 0.05 | -0.01 | 0.03 | — |
| Weighted avg. shares (diluted) | 126.15M | 125.75M | 125.55M | — | 125.41M | 122.56M | 124.63M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $287.91M | $292.67M | $288.25M | $286.36M | $280.36M | $286.38M | $265.07M | $254.16M |
| Receivables | $2.13M | $2.08M | $1.76M | $3.29M | $1.14M | $1.14M | $1.47M | $1.95M |
| Inventory | $46.29M | $42.10M | $46.45M | $44.51M | $45.59M | $43.27M | $48.61M | $52.34M |
| Current assets | $366.13M | $370.84M | $357.69M | $352.44M | $344.06M | $346.10M | $330.60M | $326.05M |
| PP&E, net | $212.10M | $201.81M | $191.32M | $187.45M | $182.58M | $177.16M | $173.79M | $170.46M |
| Total assets | $792.15M | $772.32M | $736.41M | $720.92M | $706.92M | $701.90M | $682.75M | $676.49M |
| Current liabilities | $162.23M | $163.48M | $153.28M | $150.13M | $132.06M | $135.53M | $122.61M | $130.35M |
| Total liabilities | $388.80M | $380.33M | $360.60M | $353.19M | $337.30M | $340.45M | $328.67M | $336.42M |
| Shareholders' equity | $403.35M | $391.99M | $375.81M | $367.73M | $369.62M | $361.45M | $354.09M | $340.07M |
| Cash flow statement | ||||||||
| Operating cash flow | $24.72M | $29.62M | $24.51M | $23.25M | $17.97M | $40.20M | $29.36M | $19.91M |
| Capital expenditure | $26.70M | $22.86M | $16.14M | $15.12M | $19.49M | $16.29M | $16.15M | $17.72M |
| Free cash flow | -$1.98M | $6.75M | $8.37M | $8.13M | -$1.52M | $23.91M | $13.21M | $2.19M |
| Investing cash flow | -$26.70M | -$22.86M | -$16.14M | -$15.12M | -$19.49M | -$16.29M | -$16.15M | -$17.72M |
| Financing cash flow | -$2.83M | -$2.30M | -$6.16M | -$2.31M | -$4.61M | -$2.77M | -$2.30M | $1.21M |
| Depreciation & amortization | $14.43M | $14.07M | $13.77M | $13.10M | $12.53M | $12.49M | $12.16M | $12.33M |
| Stock-based compensation | $8.55M | $9.90M | $11.39M | $6.28M | $7.03M | $8.90M | $12.33M | $8.63M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.